Nottingham Genomics Laboratory Service (NGLS)

The Nottingham Genomics Laboratory Service (NGLS) forms part of the integrated ‘East Genomic Laboratory’ (East GLH) service. NGLS is a UKAS accredited medical laboratory No. 8031. 

The East GLH is responsible for delivery of the genomic tests defined in the new National Genomic Test Directories.  The tests will be either delivered locally or via the East GLH laboratory hub at Addenbrooke’s Hospital, Cambridge. For current turnaround times please see table below.

By sending a sample, accompanied by a completed laboratory request form, the user enters into a service agreement for the Nottingham Genomics Laboratory Service (NGLS) to provide the service or test requested and agrees to the terms and conditions.

For further details of the tests delivered locally, select the links below to go to the pages for the Cytogenetics, Molecular Genetics and Molecular Diagnostics sections of the laboratory. 

Information about updates to genomic testing can be found on the East GLH website at East Genomics Updates. If you are interested in receiving regular updates about genomic testing in the East GLH you can sign up here — East Genomics Update Form.

From July 2025, UKAS accreditation for the service has been fully reinstated under ISO 15189:2022. As part of the reinstatement there was also a successful merger to include the whole Nottingham Genomics Laboratory Service under a single accreditation schedule (8031). Please see letter to users for further details.

East GLH and Nottingham University Hospitals NHS Trust comply with the Data Protection Act and the General Data Protection Regulation (GDPR) and take all possible care to maintain security and confidentiality of personal data.

When required by law or contractual obligation the laboratory will release confidential information. Any request to share patient information is managed and approved in accordance with NUH policies.  

Further information on how patient data is maintained can be found here:

Data Requests & Your Privacy | NUH

 

Page last updated 07/10/2025 Please note that if printed, this information is only valid on the day of printing

Current turnaround times

November 2025
Clinical Urgency Example Tests NHSE Target TAT (Days) Percentage within Standard Average TAT (Mean days)
Rare Disease Cytogenomics
Urgent - Rapid Microarray / karyotypes for prenatal / urgent postnatal (e.g. neonatal referrals) 14 93% 9.4
Non-urgent - Standard Standard paediatric or fetal loss microarray 42 89% 36.1
Non-urgent - Standard Postnatal karyotyping (e.g. fertility or familial microarray follow-up) 42 84% 35.8
Rare Disease Molecular
Urgent – Ultra Rapid QF-PCR for rapid trisomy detection 3 69% 2.4
Urgent – Ultra Rapid PCR based prenatal diagnosis 3 80% 3.4
Urgent – Ultra Rapid Targeted tests where the result is needed urgently 14 100% 6.7
Urgent – Rapid Predictive testing 14 88% 11.4
Non-Urgent – Standard Rare disease single gene screening, known familial variant testing & standard STR based analysis 42 97% 35.6
Non-Urgent – Standard Rare disease small panel testing (<10 genes) 42 85% 39.1
Non-Urgent – Complex Standard WGS 84 75% 77
Haem-Onc Cytogenomics
Urgent – Ultra Rapid Urgent haemato-oncology FISH PML::RARA 3 50% 3.5
Urgent – Ultra Rapid Urgent haemato-oncology FISH BCR::ABL1 3 72% 2
Urgent – Ultra Rapid Urgent haemato-oncology FISH CBF AML 3 82% 2.9
Urgent – Rapid Diagnostic CML, AML, ALL. Urgent lymphoma. 7 84% 4.1
Urgent – Rapid Follow-up haemato-oncology 14 80% 10.8
Non-urgent – Standard MDS, MPN, myeloma. Remission samples. 21 87% 15.8
Haem-Onc Molecular
Urgent – Ultra Rapid AML (FLT3, NPM1) 3 28% 4.1
Urgent – Rapid AML NGS Panel 14 (7 local) 60% 10.4
Urgent – Rapid MPN (JAK2, CALR) 21 69% 19
Urgent – Rapid Chimerism 14 72% 14.7
Urgent – Rapid Diagnostic BCR::ABL1 14 100% 7.9
Urgent – Rapid Diagnostic BCR::ABL1 (exclusion) 21 100% 10.8
  BCR::ABL1 (Monitoring) 14 58% 14.3
Solid Cancer
Urgent – Rapid FISH for solid cancers 7 100% 3
Urgent – Rapid BRAF 7 67% 5.3
Non-urgent Std NGS-targeted DNA 14 78% 12.3
Non-urgent Std NGS-targeted RNA 14 79% 11.9
Non-urgent Std FISH for solid cancers 14 96% 8.9